Robert Kotin

Robert Kotin

Company: University of Massachusetts

Job title: Adjunct Professor


Rob has been involved in AAV research for over 30 years starting as post-doctoral fellow where he discovered a common integration site on human chromosome 19, AAVS1. During a 20 year career as head of the Gene Therapy and Molecular Virology lab at the National Institutes of Health, Rob continued both basic AAV research and vector development. His lab’s accomplishments included demonstrating that AAV4 and AAV5 can be “vectorized” and invention of the baculovirus / Sf9 manufacturing platform. Since leaving the NIH in 2014, Rob has been involved in biotechnology companies including Voyager Therapeutics and is the scientific founder of Generation Bio. In addition, Rob has an appointment at the University of Massachusetts Medical School where he has maintained a funded research program.


Live Presenter Q&A 4:30 pm

Read more

day: Day One

Adeno-Associated Virus Vectors for Hemophilia Gene Therapy 4:10 pm

• rAAV manufacturing capacity for clinical and nonclinical research • Vector quality and research outcomes • Clinical benefit and persistence and safetyRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.